238 related articles for article (PubMed ID: 35311109)
1. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study.
Iurlo A; Cattaneo D; Artuso S; Consonni D; Abruzzese E; Binotto G; Bocchia M; Bonifacio M; Castagnetti F; Galimberti S; Gozzini A; Iezza M; Latagliata R; Luciano L; Maggi A; Miggiano MC; Pregno P; Rege-Cambrin G; Russo S; Scortechini AR; Tafuri A; Tiribelli M; Fava C; Rosti G; Foa R; Breccia M; Saglio G
Front Oncol; 2022; 12():839915. PubMed ID: 35311109
[TBL] [Abstract][Full Text] [Related]
2. Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.
Iurlo A; Cattaneo D; Consonni D; Castagnetti F; Miggiano MC; Binotto G; Bonifacio M; Rege-Cambrin G; Tiribelli M; Lunghi F; Gozzini A; Pregno P; Abruzzese E; Capodanno I; Bucelli C; Pizzuti M; Artuso S; Iezza M; Scalzulli E; La Barba G; Maggi A; Russo S; Elena C; Scortechini AR; Tafuri A; Latagliata R; Caocci G; Bocchia M; Galimberti S; Luciano L; Fava C; Foà R; Saglio G; Rosti G; Breccia M
Front Pharmacol; 2023; 14():1154377. PubMed ID: 37033642
[TBL] [Abstract][Full Text] [Related]
3. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
4. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety.
Laganà A; Scalzulli E; Bisegna ML; Carmosino I; Ielo C; Costa A; Torrieri L; Totaro M; Martelli M; Breccia M
Expert Opin Drug Saf; 2024 Jun; ():1-11. PubMed ID: 38873693
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.
Martín Roldán A; Sánchez Suárez MDM; Alarcón-Payer C; Jiménez Morales A; Puerta Puerta JM
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242605
[TBL] [Abstract][Full Text] [Related]
6. Treatment-Free Remission in Real-World Chronic Myeloid Leukemia Patients: Insights from German Hematology Practices.
Dengler J; Tesch H; Jentsch-Ullrich K; Gerhardt A; Schulte C; Lipke J; Löwe G; Kiani A
Acta Haematol; 2022; 145(6):603-610. PubMed ID: 35908542
[TBL] [Abstract][Full Text] [Related]
7. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
8. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Etienne G; Dulucq S; Bauduer F; Adiko D; Lifermann F; Dagada C; Lenoir C; Schmitt A; Klein E; Madene S; Fort MP; Bijou F; Moldovan M; Turcq B; Robbesyn F; Durrieu F; Versmée L; Katsahian S; Faberes C; Lascaux A; Mahon FX
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899879
[No Abstract] [Full Text] [Related]
9. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
10. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Cheng F; Li Q; Cui Z; Hong M; Li W; Zhang Y
Front Oncol; 2023; 13():1146108. PubMed ID: 37091188
[TBL] [Abstract][Full Text] [Related]
11. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.
Costa A; Abruzzese E; Latagliata R; Mulas O; Carmosino I; Scalzulli E; Bisegna ML; Ielo C; Martelli M; Caocci G; Breccia M
J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202280
[TBL] [Abstract][Full Text] [Related]
14. De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.
Luo J; Du X; Lou J; Wu J; Ma L; Huang J; Wang L; Tu C; Liu Z; Chen L; Tan Y; Luo D; Liang H; Yin C; Cao R; Zhou X; Liu Q; Liu X; Xu N
EJHaem; 2022 Nov; 3(4):1220-1230. PubMed ID: 36467815
[No Abstract] [Full Text] [Related]
15. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
16. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26
Pacelli P; Santoni A; Sicuranza A; Abruzzese E; Giai V; Crugnola M; Annunziata M; Galimberti S; Iurlo A; Luciano L; Sorà F; Fava C; Bestoso E; Marzano C; Cartocci A; Defina M; Sammartano V; Cencini E; Raspadori D; Bocchia M
Front Pharmacol; 2023; 14():1194712. PubMed ID: 37305536
[No Abstract] [Full Text] [Related]
17. Prognostic Significance of Transcript-Type
Molica M; Abruzzese E; Breccia M
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
[TBL] [Abstract][Full Text] [Related]
18. Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.
Chen H; Wen Y; Zeng Y; Lin L; Sun B; Zhu H; He H; Wang X; Zou W; Zheng C; Zheng L; Huang J; Pang L; Huang J; Zhang Y; Lin H; Liu Z; Zhu W; Wang Q; Zhou X; Liu X; Qu H; Liu Z; Du X; Xu N
Oncol Ther; 2024 Mar; 12(1):131-145. PubMed ID: 38104036
[TBL] [Abstract][Full Text] [Related]
19. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
Castagnetti F; Binotto G; Capodanno I; Billio A; Calistri E; Cavazzini F; Crugnola M; Gozzini A; Gugliotta G; Krampera M; Lucchesi A; Merli A; Miggiano MC; Minotto C; Poggiaspalla M; Salvucci M; Scappini B; Tiribelli M; Trabacchi E; Rosti G; Galimberti S; Bonifacio M
Target Oncol; 2021 Nov; 16(6):823-838. PubMed ID: 34661826
[TBL] [Abstract][Full Text] [Related]
20. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
